{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:58:32Z","timestamp":1780491512535,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:00:00Z","timestamp":1509753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10067-017-3890-4","type":"journal-article","created":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T03:25:05Z","timestamp":1509765905000},"page":"549-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis"],"prefix":"10.1007","volume":"37","author":[{"given":"Colleen K.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle R.","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Cafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Vehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,4]]},"reference":[{"key":"3890_CR1","unstructured":"Humira Package Insert (2016). \nhttp:\/\/www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"3890_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0706290","journal-title":"N Engl J Med"},{"key":"3890_CR3","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3899\/jrheum.120110","volume":"39","author":"T Beukelman","year":"2012","unstructured":"Beukelman T, Ringold S, Davis TE et al (2012) Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 39:1867\u20131874. \nhttps:\/\/doi.org\/10.3899\/jrheum.120110","journal-title":"J Rheumatol"},{"key":"3890_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","volume":"67","author":"R Burgos-Vargas","year":"2015","unstructured":"Burgos-Vargas R, Tse SM, Horneff G et al (2015) A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken) 67:1503\u20131512. \nhttps:\/\/doi.org\/10.1002\/acr.22657","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3890_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3899\/jrheum.120583","volume":"40","author":"ME Zannin","year":"2013","unstructured":"Zannin ME, Birolo C, Gerloni VM et al (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40:74\u201379. \nhttps:\/\/doi.org\/10.3899\/jrheum.120583","journal-title":"J Rheumatol"},{"key":"3890_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB Putte van de","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508\u2013516. \nhttps:\/\/doi.org\/10.1136\/ard.2003.013052","journal-title":"Ann Rheum Dis"},{"key":"3890_CR7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P et al (2007) Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut 56:1232\u20131239","journal-title":"Gut"},{"key":"3890_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846\u2013855. \nhttps:\/\/doi.org\/10.7326\/0003-4819-157-12-201212180-00004","journal-title":"Ann Intern Med"},{"key":"3890_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1365-2133.2012.11041.x","volume":"167","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Sobell JM, Crowley JJ et al (2012) Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 167:658\u2013667. \nhttps:\/\/doi.org\/10.1111\/j.1365-2133.2012.11041.x","journal-title":"Br J Dermatol"},{"key":"3890_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/apt.12863","volume":"40","author":"D Wolf","year":"2014","unstructured":"Wolf D, D\u2019Haens G, Sandborn WJ et al (2014) Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 40:486\u2013497. \nhttps:\/\/doi.org\/10.1111\/apt.12863","journal-title":"Aliment Pharmacol Ther"},{"key":"3890_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/MIB.0000000000000715","volume":"22","author":"MC Dubinsky","year":"2016","unstructured":"Dubinsky MC, Rosh J, Faubion WA Jr et al (2016) Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn\u2019s disease. Inflamm Bowel Dis 22:886\u2013893. \nhttps:\/\/doi.org\/10.1097\/MIB.0000000000000715","journal-title":"Inflamm Bowel Dis"},{"key":"3890_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170259","volume":"12","author":"F Aljebab","year":"2017","unstructured":"Aljebab F, Choonara I, Conroy S (2017) Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One 12:e0170259. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0170259","journal-title":"PLoS One"},{"key":"3890_CR13","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, ten Klooster PM et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810\u20131817. \nhttps:\/\/doi.org\/10.1002\/art.39626","journal-title":"Arthritis Rheumatol"},{"key":"3890_CR14","unstructured":"A LOOK AT TARGETED IMMUNE MODULATORS. \nWWW.ICER-REVIEW.ORG\n\n 1. Accessed 9\/26\/2017"},{"key":"3890_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/acr.20337","volume":"63","author":"WJ Ungar","year":"2011","unstructured":"Ungar WJ, Costa V, Hancock-Howard R et al (2011) Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 63:111\u2013119. \nhttps:\/\/doi.org\/10.1002\/acr.20337","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3890_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ et al (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22:847\u2013861. \nhttps:\/\/doi.org\/10.1016\/j.berh.2008.09.008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3890_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/09546634.2015.1136385","volume":"27","author":"TH Zhu","year":"2016","unstructured":"Zhu TH, Nakamura M, Abrouk M et al (2016) Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J Dermatolog Treat 27:406\u2013413. \nhttps:\/\/doi.org\/10.3109\/09546634.2015.1136385","journal-title":"J Dermatolog Treat"},{"key":"3890_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11926-012-0310-2","volume":"15","author":"ML Mannion","year":"2013","unstructured":"Mannion ML, Beukelman T (2013) What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep 15:310\u2013312. \nhttps:\/\/doi.org\/10.1007\/s11926-012-0310-2","journal-title":"Curr Rheumatol Rep"},{"key":"3890_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","volume":"3","author":"P Nash","year":"2016","unstructured":"Nash P, Vanhoof J, Hall S et al (2016) Randomized crossover comparison of injection site pain with 40 mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther 3:257\u2013270. \nhttps:\/\/doi.org\/10.1007\/s40744-016-0041-3","journal-title":"Rheumatol Ther"},{"key":"3890_CR20","unstructured":"Observational study of pediatric rheumatic diseases: the CARRA Registry. \nClinicalTrials.gov\n\n. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02418442?term=carra+registry&rank=2\n\n. Accessed 1 Feb 2017"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3890-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T06:47:23Z","timestamp":1516430843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3890-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3890"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3890-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,4]]}}}